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Abstract 
Non-alcoholic fatty liver disease (NAFLD), characterized by lipid deposition within the liver 
(intrahepatocellular lipid, IHCL), is associated with insulin resistance and the metabolic 
syndrome. It has been suggested that impaired skeletal muscle mitochondrial function may 
contribute to ectopic lipid deposition, and the associated metabolic syndrome, by altering 
post-prandial energy storage. To test this hypothesis, we performed a cross-sectional study of 
17 patients with NAFLD (mean ± SD; age 45±11 y; BMI 31.6±3.4 kg/m2) and 18 age- and 
BMI-matched healthy controls (age 44±11 y; BMI 30.5±5.2 kg/m2). We determined body 
composition by magnetic resonance imaging (MRI), IHCL and intramyocellular (soleus and 
tibialis anterior) lipids (IMCL) by proton magnetic resonance spectroscopy (1H-MRS) and 
skeletal muscle mitochondrial function by dynamic phosphorus magnetic resonance 
spectroscopy (31P-MRS) of quadriceps muscle. Although matched for BMI and total 
adiposity, after statistical adjustment for gender, patients with NAFLD (defined by IHCL ≥ 
5.5%) had higher IHCL (25±16 vs. 2±2 %; p<0.0005), and a higher prevalence of the 
metabolic syndrome (76 vs. 28%) compared with healthy controls. Despite this, visceral: 
subcutaneous fat ratio, IMCL and muscle mitochondrial function were similar between the 
NAFLD and control groups, with no significant difference in the rate constants of post-
exercise PCr recovery (1.55±0.4 vs. 1.51±0.4 min-1), a measure of muscle mitochondrial 
function. Impaired muscle mitochondrial function does not appear to underlie ectopic lipid 
deposition, or the accompanying features of the metabolic syndrome, in patients with 
NAFLD. 
 
Keywords: Non-alcoholic fatty liver disease, lipid deposition, mitochondrial function, 
skeletal muscle 
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Introduction  
Non-alcoholic fatty liver disease (NAFLD) describes a pathological spectrum in which lipid 
excessively accumulates within the liver, with or without associated necroinflammatory 
changes. The association of NAFLD with insulin resistance, the metabolic syndrome and 
type 2 diabetes mellitus is well established [1]. Petersen et al. [2] highlighted the role played 
by skeletal muscle, and associated insulin resistance, in the development of the metabolic 
syndrome and NAFLD, showing that reduced muscle glycogen synthesis and compensatory 
increased hepatic de novo lipogenesis result in a characteristic dyslipidaemia (increased 
plasma triglycerides and lower HDL) and increased hepatic triglyceride synthesis;  
furthermore, exercise-induced reversal of muscle insulin resistance, which dramatically 
increased postprandial net muscle glycogen synthesis, reduced hepatic triglyceride synthesis 
(by ~40%) [3].  
 
Although it is well established that intracellular lipid accumulation within muscle and liver 
accompanies systemic insulin resistance, and mechanisms have been proposed for causal 
pathophysiological links between lipid accumulation and impaired insulin signaling [4, 5] the 
extent to which mitochondrial dysfunction contributes to accumulation of lipid in non-
adipose sites, including skeletal muscle and liver, remains contentious. Some studies have 
suggested that defects in skeletal muscle mitochondrial oxidative capacity might contribute to 
ectopic lipid accumulation [2, 3, 6, 7] while others have found no significant association 
between ectopic fat deposition and altered mitochondrial function [8, 9]. The experimental 
literature in this area has been complicated by the variety of ways in which mitochondrial 
function can be assessed [10].  
 
A way to study skeletal muscle mitochondrial function noninvasively in vivo is phosphorus 
magnetic resonance spectroscopy (31P MRS) [10]. We set out in this study to use 31P MRS, 
together with MR-based assessments of muscle and liver cell triglyceride and whole-body 
adipose tissue distribution, to study the relationship between these in patients with NAFLD 
compared to normal subjects matched for age, gender, BMI and whole body fitness. 
 
 
Methods 
Participants  
All participants were sedentary (<2h low intensity physical activity per week) non-smokers 
with no history of excessive alcohol intake (average weekly consumption <14 units for 
females and <21 units for males). None had a history of ischaemic heart disease or type 2 
diabetes mellitus, and their fasting glucose levels were normal. There were no 
contraindications to exercise or MRI scanning.  
 
NAFLD patients: 17 patients with NAFLD (mean±SD; age 45±11 y; BMI 31.6±3.4 kg m-2) 
were recruited by a single, experienced hepatologist at each of two tertiary referral specialist 
liver clinics. The diagnosis of NAFLD was made, in patients who had been referred for 
investigation of raised plasma transaminase levels, after careful exclusion of drug causes, 
viral hepatitis (negative hepatitis B and C serology), autoimmune hepatitis and primary 
biliary cirrhosis (negative auto-antibody screen) or metabolic disorders such as α1-antitrypin 
deficiency or Wilson’s disease (normal α1 antitrypsin and caeruloplasmin concentrations). 
Allocation to the NAFLD group was confirmed once liver triglyceride content was measured 
as ≥ 5.5%  by proton magnetic resonance spectroscopy (1H-MRS) [11]. 
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Control subjects: 18 age- and BMI-matched healthy controls (age 44±11 y; BMI 30.5±5.2 kg 
m-2) were recruited via local advertisement. None were taking any prescribed medication and 
all had normal plasma levels of liver transaminases. Allocation to the control group was 
confirmed once liver triglyceride content was measured as ≤ 5.5%.  
 
Ethical considerations  
The study conformed to the Declaration of Helsinki and was approved by the local NHS 
research ethics committee. Participants were informed of the methods verbally and in writing 
before providing written informed consent. 
 
Research Design 
This was a cross-sectional study. Participants reported to the laboratory on two occasions. All 
measurements were performed following an overnight fast, 12h abstinence from caffeine and 
24h abstinence from alcohol and strenuous exercise. The first visit entailed anthropometric 
and blood pressure measurements, biochemical measurements and a maximal oxygen 
consumption test. The second visit was for all MR-based measurements: abdominal MRI, 1H-
MRS of liver, and 31P-MRS and 1H-MRS of leg muscle.  
 
Anthropometric and blood pressure measurements: After a full medical history, a single 
observer (AI) performed all the anthropometric assessments (weight, height, waist and hip 
circumference) and blood pressure measurements. 
 
Biochemical measurements: Following an overnight fast a blood sample was taken. Plasma 
was analysed using the Olympus AU2700 analyser (Beckman Coulter, High Wycombe, UK) 
with standard proprietary reagents as follows: glucose with hexokinase, total cholesterol and 
high-density lipoprotein (HDL) with cholesterol esterase/oxidase, triglyceride with glycerol 
kinase and liver enzymes including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and gamma-glutamyltransferase (GGT) with International 
Federation of Clinical Chemistry (IFCC) kinetic UV (without pyridoxal phosphate activation). 
The intra- and inter-assay coefficient of variation was ≤10%. Low-density lipoprotein (LDL) 
was calculated according to the Friedewald formula. All laboratory assays were performed in 
the clinical biochemistry laboratory at University Hospital Aintree. 
 
Metabolic syndrome: The diagnosis of the metabolic syndrome was based on the national 
Cholesterol Education Program Adult Treatment Panel III criteria [12] when ≥3 of the 
following are present: i) central obesity: waist circumference ≥ 102 cm (male), ≥ 88 cm 
(female); dyslipidemia: ii) TG ≥ 1.7 mmol/L (150 mg/dl) and iii) HDL-C < 40 mg/dL (male), 
< 50 mg/dL (female); iv) hypertension: systolic blood pressure ≥ 130/85 mmHg; v) 
hyperglycaemia: fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl). 
 
Cardiorespiratory fitness (VO2peak) test: Fitness was assessed on a treadmill ergometer 
following the Bruce protocol [13]. After an initial 2 min warm up at 2.2 km/h on the flat, the 
initial workload was set at 2.7 km/h at 5° grade; step-wise increments in speed and grade 
were made every minute thereafter. Heart rate (Polar Electro Oy, Kempele, Finland) and rate 
of perceived exertion were monitored continuously [14]. VO2peak 
was calculated from expired 
gas fractions (Oxycon Pro, Jaegar, Hochberg, Germany) as the highest consecutive 15s 
period of gas exchange data occurring in the last minute before volitional exhaustion. 
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MR measurements Measurements of total abdominal, abdominal subcutaneous and visceral 
fat by whole-body MRI, and of intrahepatocellular lipid (IHCL) and intramyocellular lipid 
(IMCL) by 1H MRS, were carried out using a Siemens 1.5T Symphony MR scanner 
(Siemens AG, Erlangen, Germany) as previously described [15-18]. 31P MRS assessments of 
muscle mitochondrial function in quadriceps were carried out using a Siemens 3T Trio MR 
scanner (Siemens AG, Erlangen, Germany) using an isometric knee extension exercise 
protocol similar to one we employed previously for studies of calf muscle during plantar 
flexion [19]. Subjects lay supine (secured with a Velcro strap across the hips) with the right 
knee flexed over a rigid foam support in a custom-built rig permitting isometric knee 
extension exercise against a strap across the anterior lower shin/ankle connected to an 
aluminum bar fitted with a strain gauge. 31P MRS data were acquired from right quadriceps 
muscle using a dual-tuned 18cm/15cm diameter 31P/1H surface coil (RAPID Biomedical, 
Rimpar, Germany), Velcro-strapped to the anterior thigh (midway between anterior superior 
iliac spine and patella). After automated set-up and manual shimming using tissue water, an 
8-scan fully relaxed (TR=15s) spectrum and a 32-scan partially saturated (TR=2s) resting 
spectrum were collected.  The exercise protocol consisted of 5 min rest followed by 2 bouts 
of isometric exercise each followed by 7 min recovery periods, while spectra were collected 
(TR=2) every 8 s paced at 0.5 Hz (1 s on, 1 s off) by an audible cue, exercise force being fed 
back visually via an LED display visible at the end of the bore through a head-mirror. Two 
exercise intensities were used, corresponding to 70% and 90% of maximal voluntary 
contraction established in 3 brief trials prior to MRS acquisition (in pilot experiments these 
intensities were found to give acceptable PCr depletion with minimal acidification in typical 
subjects). All spectra were acquired with Nuclear Overhauser enhancement (NOE): 1H spins 
were saturated by 10 radiofrequency pulses (900 flip angle), 5 ms pulse duration, and 10 ms 
interpulse delay. Block MRS data output files from exercise-recovery acquisitions were 
converted to text using a specially-written MATLAB routine. All 31P MRS data were 
processed using the java-based Magnetic Resonance User Interface (jMRUI v.3.0), using the 
AMARES time-domain fitting algorithm. Data were fitted assuming Lorentzian lineshapes 
for PCr, Pi, PDE, PME, NADP and ATP (β-ATP a 1:2:1 triplet, α-ATP and γ-ATP both 1:1 
doublets). The chemical shift of the inorganic phosphate (Pi) peak relative to phosphocreatine 
(PCr) (σ parts per million) was used by standard means to determine intracellular pH. PCr 
recovery time courses were fitted to a monoexponential function to estimate the recovery rate 
constant (k min-1). In the absence of appreciable changes in pH (as here), this is accepted as a 
measure of effective muscle mitochondrial function, the latter being a system property which 
reflects cardiovascular oxygen supply and mitochondrial oxygen usage [20]. As the PCr 
recovery rate constant did not differ significantly between the two exercise intensities, and as 
pH changes were small throughout, values of k are presented as mean of the two intensities to 
reduce variability [19]. 
 
Statistical analysis 
The primary outcome variable for this study was the PCr recovery rate constant k. Groups 
were compared using the two-sample t-test or Mann-Whitney U tests if distributional 
assumptions were not met following logarithmic or Box-Cox transformation. In order to 
assess the sensitivity of some results to the gender imbalance between groups we also 
compared groups using linear regression/ANCOVA, adjusting for sex. Poisson regression 
was used to compare the number of metabolic components between groups. Spearman’s 
correlation coefficient (rs) was used to describe the strength of association between 
continuous variables. Statistical significance was delimited as P<0.05. Data are presented as 
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mean(95% confidence intervals), unless stated otherwise and exact P values are cited (values 
of P of “0.000” provided by the statistics package are reported as “<0.001”). All analyses 
wree conducted using Stata 13 (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP). 
 
Results  
Clinical characteristics (Table 1) 
Patients with NAFLD and control subjects were matched with no significant differences in 
age, body mass index, fat mass and cardiorespiratory fitness (even when normalised for body 
weight) (Table 1). The NAFLD group had a significantly greater waist circumference [7.9cm 
(95% CI=0.6, 15.1); P=0.03], although when adjusted for total body weight this difference 
was no longer significant.  
 
Biochemical characteristics and components of the metabolic syndrome (Table 1) 
Patients with NAFLD had higher ALT [61 mU/l (95% CI= 30, 83) vs. 21 mU/l (95% CI= 16, 
32); P<0.001] and GGT [48 mU/l (95% CI= 42, 79) vs. 28 mU/l (95% CI= 23, 40); P=0.03] 
when compared with controls but AST was not significantly different [24 mU/l (95% CI= 10, 
43) vs. 21 mU/l (95% CI= 16, 25); P<0.001]. Although total cholesterol was not significantly 
different, patients with NAFLD had a significantly higher triglyceride [2.3 mU/l (95% CI= 
1.6, 3.4) vs. 1.3 mU/l (95% CI= 1.0, 2.3); P=0.007] and lower HDL cholesterol [1.0 mmol/l 
(95% CI= 0.9, 1.2) vs. 1.2 mmol/l (95% CI= 1.1, 1.5); P=0.007]. Fasting glucose did not 
differ between the two groups (Table 1). The prevalence of metabolic syndrome was greater 
in the NAFLD group (76% vs. 28%, P=0.004) and the patients with NAFLD had a higher 
mean number of components of the metabolic syndrome (2.9±1.0 vs. 1.8 ±1.2; P=0.05) 
(Figure 1). 
 
MR-derived measures of adipose tissue mass (Figure 1) 
After statistical adjustments for gender, total abdominal fat did not differ between the two 
groups, nor did the amount visceral fat in patients with NAFLD (Figure 1). VAT: SAT ratio 
was similar in NAFLD patients compared to controls. As expected, liver fat was higher in 
NAFLD patients (Figure 1) but IMCL in both soleus and tibialis anterior was not 
significantly different between the two groups (Figure 1).  
 
Cytosolic pH and phosphorus metabolites in resting muscle (Table 1)  
There were no significant differences in resting muscle intracellular pH (pHi) between the 
two groups and there was no significant cytosolic acidification during exercise in either group.  
The resting phosphate metabolite ratios inorganic phosphate:ATP and PCr:ATP did not differ 
significantly between the two groups nor was there any significant difference in the amount 
of PCr depletion during exercise.  
 
Assessment of muscle mitochondrial function (Figure 2) 
The post exercise PCr recovery rate constant did not differ significantly between the two 
groups [1.62 min-1 (95% CI= 0.34, 1.86) vs. 1.50 min-1 (95% CI= 1.18, 1.77); P=0.81].  
 
Relationship of muscle mitochondrial function to the metabolic syndrome (MS) 
Comparing the two groups according to the presence (n=18) or absence (n=17) of the 
metabolic syndrome, we were not able to detect any significant difference in the PCr 
recovery rate constant [0.03 min-1 (95% CI=-0.24, 0.30), P=0.83] (Figure 3). Similarly, 
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examining the number of components of the metabolic syndrome in both controls and 
NAFLD patients we found no correlation with the PCr recovery rate constant (r= -0.03, 
P=0.83).  
 
Correlation of muscle mitochondrial function with biochemical and body composition 
measurements 
There were no significant correlations between PCr recovery constant and age, weight, BMI, 
fat mass, VO2peak, any biochemical measure or any MR-derived measure of body composition. 
 
 
Discussion  
The major finding of this study is that skeletal muscle mitochondrial function, determined 
using dynamic 31P-MRS measurements after exercise, is similar in patients with NAFLD to 
age-, BMI- and cardiorespiratory fitness-matched controls. The similarity in mitochondrial 
function was observed despite greater liver (but not visceral) fat deposition and more 
numerous components of the metabolic syndrome in patients with NAFLD suggesting that 
factors other than skeletal muscle mitochondrial dysfunction play a pathophysiological role in 
the metabolic phenotype of NAFLD. 
 
Analysis of the post-exercise PCr recovery kinetics in the vastus lateralis muscle quantifies 
the in vivo mitochondrial oxidative capacity of skeletal muscle because, during recovery from 
exercise, PCr is resynthesized purely as a consequence of oxidative ATP synthesis. Such 
measures correlate with ex vivo measurements of muscle mitochondrial function and whole-
body measures of aerobic fitness in type 2 diabetic patients [21, 22], similarly to healthy 
controls [22]. We observed no correlation with aerobic fitness in the current study, which 
could potentially be due to the small range of cardiorespiratory fitness observed in both study 
groups. 
 
A number of reports [10] have implicated mitochondrial dysfunction in skeletal muscle in the 
development of insulin resistance. In a cohort of healthy, lean, insulin-resistant offspring of 
patients with type 2 diabetes, a 31P MRS-derived measurement taken to reflect mitochondrial 
ATP production in skeletal muscle [10] was found to be  ~30% lower (associated with ~60% 
lower insulin-stimulated glucose uptake by muscle and a ~80% greater IMCL than in healthy 
controls [23]. In a related study in a cohort of insulin-resistant offspring, a reduction in 
muscle mitochondrial density (measured in muscle biopsy specimens) was accompanied by 
increased IMCL, reduced insulin-stimulated glucose uptake and impairment of insulin signal 
transduction [24]. In the elderly, the same relationship was observed between claimed 
measures of mitochondrial dysfunction, ectopic fat accumulation and insulin resistance [6]. 
However, proposals of a causal relationship between muscle mitochondrial dysfunction, 
increased muscle cellular triglyceride accumulation and disordered post-receptor insulin 
signaling have been called into question by animal [25] and  human [26] studies.  Slowed PCr 
recovery is evident relative to controls matched for age, gender, BMI and fitness in e.g. 
primary congenital insulin resistance (7 patients vs. 12 controls) [27] and congenital 
lipodystrophy (7 patients vs. 15 controls) [20].  These studies show that studies of the present 
kind and size are capable of demonstrating defects of muscle oxidative capacity, relative to 
fitness-matched controls; this supports the inference from our failure to detect any such 
difference that no such abnormalities exists in our NAFLD patients.  In both primary 
congenital insulin resistance and congenital lipodystrophy this impaired muscle oxidative 
function must be a consequence or simply an accompaniment of insulin resistance, since it 
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cannot be its cause  ADDIN EN.CITE [). Our present negative finding suggests that muscle 
mitochondrial dysfunction is not a primary factor in the development of NAFLD and its 
cardiometabolic sequelae, but rather may occur as a secondary phenomenon.  
 
We did not observe any difference in IMCL between NAFLD and control groups. The 
significance of IMCL is controversial, with some studies suggesting that muscle lipid 
accumulation is an early and critical event in the development of insulin resistance [28]. In 
contrast, similar to Thomas et al. [29], we found no correlation between IMCL and liver fat 
and, like Machado and colleagues [9] we found no relationship between IMCL and muscle 
mitochondrial dysfunction [6, 26]. 
 
There is good evidence that skeletal muscle insulin resistance is implicated in the 
development of NAFLD and the metabolic syndrome, and that this may be reversed with 
exercise [2, 3]. As the primary outcome measure of the current study was the rate constant of 
PCr recovery i.e. mitochondrial oxidative capacity, in relation to liver fat content, we were 
less concerned with measures of insulin sensitivity. The NAFLD patients had a higher mean 
fasting insulin concentration and HOMA-IR, but this only approached statistical significance 
(P=0.08). However, the limitations of HOMA-IR have been previously discussed and it has 
been suggested that surrogate estimates of insulin sensitivity (including HOMA-IR) can lead 
to conclusions that are totally different from those based on the results of euglycaemic–
hyperinsulinaemic clamp measurements. Thus in the current study, in the absence of 
measures of insulin sensitivity using more sensitive, gold-standard techniques such as the 
hyperinsulinaemic, euglycaemic clamp, it would be misleading to draw conclusions on the 
relative degrees of insulin sensitivity/resistance of each individual/group.  
 
Although we could not directly examine the inter-relationship between PCr recovery constant 
and insulin resistance, we compared instead the groups with or without the metabolic 
syndrome, and according to the number of components of the metabolic syndrome. We found 
no difference in PCr rate constant between those with or without the metabolic syndrome nor 
did we observe any relationship between the number of components and the PCr rate constant. 
A recent paper [30] has addressed the issue of a connection (possibly causal) between muscle 
energy metabolism, liver steatosis and insulin resistance by reanalysing data collected 
together from 6 previously-published studies [8, 31-35] of the research group. The total study 
population comprised 113 (52 male and 61 female) participants of whom 87 had normal 
glucose tolerance, 16 had impaired fasting glucose and/or glucose intolerance, and 10 had 
frank type 2 diabetes. This large study population permitted the identification of some 
interesting correlations; the rate of muscle Pi-ATP exchange, measured by magnetisation 
transfer, correlated negatively with hepatic lipid content and haemoglobin A1c (HbA1c), and 
positively with insulin sensitivity; there was no relation to body mass, muscle triglyceride.  
However, as alluded to above, there are serious problems with Pi-ATP exchange as a 
metabolic marker of mitochondrial metabolism [10]. It is now generally acknowledged that 
no measure of resting ATP turnover can be interpreted in terms of muscle oxidative capacity, 
which is by contrast the standard interpretation of measures derived from post-exercise PCr  
kinetics (the simplest of which is the rate constant, as used in the present work). In the light 
of this, the Pi-ATP exchange rate is sometimes regarded as a measure of ‘mitochondrial 
activity’ and’ ATP synthase flux’ [30]. However, the rate of Pi-ATP exchange is 
approximately an order of magnitude larger than the actual rate of oxidative ATP turnover in 
resting muscle, the difference being likely due non-mitochondrial exchange catalysed by two 
enzymes of glycolysis [10]. Interestingly, a cross-sectional study of 15 normal subjects [36], 
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significant correlations were found between the resting Pi-ATP exchange rate and a resting-
ischaemia 31P MRS measure of resting ATP synthesis rate (despite the order-of-magnitude 
difference in absolute numbers), and PCr-recovery based measures of mitochondrial function 
(despite the logical distinctness of ATP turnover and oxidative capacity, as mentioned above, 
and for reasons which are so far unexplained [10]. This first of these correlations, together 
with some observations of clinical or experimental changes in Pi-ATP exchange in 
physiologically expected directions [37] (again, notwithstanding the order-of-magnitude 
error), is sometimes described as supporting [37] or even validating [30] the Pi-ATP 
exchange measurement. However, as almost nothing is known about what determines the 
overwhelmingly dominant non-mitochondrial component of the measurement [10], this 
interpretation remains problematic. The important point for the present work is that, although 
we cannot exclude the possibility that a larger study (nearer the 113 subjects of [10] than the 
35 we studied) would show a relationship between liver fat and a measure of muscle 
mitochondrial function, the correlation reported in [30] gives no reason to expect it.  
 
In addition to skeletal muscle, the properties of adipose tissue and adipose tissue dysfunction 
are also implicated in the deposition of ectopic fat (although not examined in this study). 
Insulin resistance in adipose tissue results in a reduced ability of insulin to suppress fatty acid 
release from adipose tissue (leading to increased free fatty acid flux to the liver) and the 
magnitude of adipose insulin resistance is inversely correlated with liver fat [38, 39]. 
Furthermore, characteristics of subcutaneous fat and defective regulation of lipid storage 
genes in subcutaneous adipose tissue may limit its expandability [40].  
 
Clinical Perspectives  
It has been suggested that impaired skeletal muscle mitochondrial function may contribute to 
ectopic lipid deposition, and the associated metabolic syndrome, by altering post-prandial 
energy storage. We provide evidence that skeletal muscle mitochondrial function is preserved 
in patients with NAFLD, compared to age, BMI and fitness-matched healthy controls, and 
cannot account for ectopic fat deposition or the high prevalence of metabolic syndrome. Thus 
it would appear that factors other than skeletal muscle mitochondrial dysfunction play a 
pathophysiological role in the metabolic phenotype of NAFLD, with available data 
suggesting skeletal muscle and adipose tissue insulin resistance play a major role.  
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Table 1. Baseline characteristics of participants reported as mean+/- SD, median(lower quartile, upper quartile) or frequency(%).  
  NAFLD (n=17) Controls (n=18) P 
Anthropometric Age (y)* 47(41,52) 47(34,51) 0.68 
 Gender (M,F) 11 (65%), 6(35%) 7(39%), 11(61%) 0.13 
 Weight (kg) 96.1±14.8 85.6±15.7 0.05 
 BMI (kg/m2) 31.5±3.4 30.53±5.24 0.5 
 % fat mass* 40.5(30.1,44.1) 34.2(29.2,44.8) 0.69 
 Waist circumference (cm)* 108.6±9 100.8±11.8 0.03 
 Systolic blood pressure* 125(120,140) 123.5(120,132) 0.62 
 Diastolic blood pressure* 82(78,88) 75(70,80) 0.03 
Biochemical AST (mU/l)* 24(10,43) 21(16,25) 0.37 
 ALT (mU/l)* 61(30,83) 21(16,32) <0.001 
 GGT (mU/l)* 48(42,79) 28(23,40) 0.03 
 Cholesterol (mmol/l)* 5.9(5.1,6.1) 5.2(4.7,5.7) 0.54 
 HDL (mmol/l)* 1.0(0.9,1.2) 1.2(1.1,1.5) 0.007 
 Triglyceride (mU/l)* 2.3(1.6,3.4) 1.3(1.0,2.3) 0.007 
 Fasting glucose (mmol/l)* 5.0(4.7,5.3) 4.8(4.4,5.1) 0.18 
 Fasting insulin * 91.2(67.2,114.6) (n=13) 78.8(55.4,86.4) (n=14) 0.11 
 HOMA-IR * 4.1(3.0,7.6) 3.2(2.7,4.3) 0.08 
Metabolic syndrome (MS) Number with MS  13/17(76 %) 5/18(28 %) 0.004 
 Components of MS¥ 2.9±1.0 1.8±1.2 0.05 
Cardiorespiratory fitness V
．
O2 max (ml/kg/min)*  23.5(20,31.3) 25.75(22.9,30) 0.69 
 V
．
O2 max/weight (ml/min)* 0.3(0.2, 0.3) 0.3(0.2,0.4) 0.14 
Muscle 31P MRS* Resting Pi/ATP*  0.56(0.49, 0.63) 0.44(0.38, 0.58) 0.09 
 Resting pH¥  7.08(7.06, 7.09) 7.08(7.06, 7.10) 0.39 
 End-exercise pH fall 0.14±0.12/ 0.12±0.13/ 0.07/ 
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-0.06±0.09 -0.01±0.09 0.62 
 Resting PCr/ATP 4.25±0.68 4.07±0.57 0.40 
 End-exercise PCr depletion (%)* 0.19(0.14, 0.26)/ 
0.35(0.24, 0.50) 
0.20(0.08, 0.29)/ 
0.32(0.12, 0.44) 
0.82/ 
0.75 
 PCr recovery rate constant (min-1)* 1.62(0.34, 1.86) 1.50(1.18, 1.77) 0.81 
Pairs of results represent 70%/90% MVC separately. 
* Mann-whitney U Test, ¥Poisson regression. 
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Figure Legends 
 
Figure 1. Body composition data demonstrating total abdominal fat, abdominal subcutaneous 
(SC) fat, visceral fat, intramyocellular fat (IMCL) of soleus muscle, liver fat and the number 
of components of the metabolic syndrome in patients with NAFLD (n=17) and age- and 
BMI-matched healthy controls (n=18).  
 
Figure 2. Post-exercise phosphocreatine (PCr) recovery rate constant, k (min-1) in patients 
with NAFLD (n=17) and age- and BMI-matched healthy controls (n=18).  
 
Figure 3. Relationship between post-exercise PCr recovery rate constant, k (min-1) and the 
number of components of the metabolic syndrome within the healthy controls (triangle) and 
patients with NAFLD (circle). 
 
References 
1 Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., 
McCullough, A. J., Natale, S., Forlani, G. and Melchionda, N. (2001) Nonalcoholic fatty 
liver disease: a feature of the metabolic syndrome. Diabetes. 50, 1844-1850 
2 Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, 
G. W., Befroy, D., Zemany, L., Kahn, B. B., Papademetris, X., Rothman, D. L. and Shulman, 
G. I. (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the 
metabolic syndrome. Proc Natl Acad Sci U S A. 104, 12587-12594 
3 Rabol, R., Petersen, K. F., Dufour, S., Flannery, C. and Shulman, G. I. (2011) 
Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo 
lipogenesis in insulin resistant individuals. Proc Natl Acad Sci U S A. 108, 13705-13709 
4 Kantartzis, K., Machann, J., Schick, F., Fritsche, A., Haring, H. U. and Stefan, N. 
(2010) The impact of liver fat vs visceral fat in determining categories of prediabetes. 
Diabetologia. 53, 882-889 
5 Samuel, V. T., Petersen, K. F. and Shulman, G. I. (2010) Lipid-induced insulin 
resistance: unravelling the mechanism. Lancet. 375, 2267-2277 
6 Johannsen, D. L., Conley, K. E., Bajpeyi, S., Punyanitya, M., Gallagher, D., Zhang, 
Z., Covington, J., Smith, S. R. and Ravussin, E. (2012) Ectopic lipid accumulation and 
reduced glucose tolerance in elderly adults are accompanied by altered skeletal muscle 
mitochondrial activity. J Clin Endocrinol Metab. 97, 242-250 
7 Szendroedi, J., Kaul, K., Kloock, L., Strassburger, K., Schmid, A. I., Chmelik, M., 
Kacerovsky, M., Kacerovsky-Bielesz, G., Prikoszovich, T., Brehm, A., Krssak, M., Gruber, 
S., Krebs, M., Kautzky-Willer, A., Moser, E., Pacini, G. and Roden, M. (2013) Lower fasting 
muscle mitochondrial activity relates to hepatic steatosis in humans. Diabetes Care 
8 Prikoszovich, T., Winzer, C., Schmid, A. I., Szendroedi, J., Chmelik, M., Pacini, G., 
Krssak, M., Moser, E., Funahashi, T., Waldhausl, W., Kautzky-Willer, A. and Roden, M. 
Cuthbertson et al. 2013   14 
 
 
 
(2011) Body and liver fat mass rather than muscle mitochondrial function determine glucose 
metabolism in women with a history of gestational diabetes mellitus. Diabetes Care. 34, 430-
436 
9 Machado, M. V., Ferreira, D. M., Castro, R. E., Silvestre, A. R., Evangelista, T., 
Coutinho, J., Carepa, F., Costa, A., Rodrigues, C. M. and Cortez-Pinto, H. (2012) Liver and 
muscle in morbid obesity: the interplay of fatty liver and insulin resistance. PLoS One. 7, 
e31738 
10 Kemp, G. J. and Brindle, K. M. (2012) What do magnetic resonance-based 
measurements of Pi-->ATP flux tell us about skeletal muscle metabolism? Diabetes. 61, 
1927-1934 
11 Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., 
Cohen, J. C., Grundy, S. M. and Hobbs, H. H. (2004) Prevalence of hepatic steatosis in an 
urban population in the United States: impact of ethnicity. Hepatology. 40, 1387-1395 
12 Expert Panel on DetectionEvaluation, T. H. B. C. A. (2001) Executive summary of 
the third report of the National Cholesterol Education Program (NCEP) expert panel on 
detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel 
III). JOURNAL-AMERICAN MEDICAL ASSOCIATION. 285, 2486-2497 
13 Bruce, R. A., Kusumi, F. and Hosmer, D. (1973) Maximal oxygen intake and 
nomographic assessment of functional aerobic impairment in cardiovascular disease* 1. Am 
Heart J. 85, 546-562 
14 Borg, G. (1998) Borg's perceived exertion and pain scales. Human Kinetics 
Publishers 
15 Gardner, C. J., Irwin, A. J., Daousi, C., McFarlane, I. A., Joseph, F., Bell, J. D., 
Thomas, E. L., Adams, V. L., Kemp, G. J. and Cuthbertson, D. J. (2012) Hepatic steatosis, 
GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance 
spectroscopy study. Eur J Endocrinol. 166, 993-1002 
16 Gardner, C. J., Richardson, P., Wong, C., Polavarapu, N., Kemp, G. J. and 
Cuthbertson, D. J. (2011) Hypothyroidism in a patient with non-alcoholic fatty liver disease. 
Bmj. 342, c7199 
17 Jones, H., Sprung, V. S., Pugh, C. J., Daousi, C., Irwin, A., Aziz, N., Adams, V. L., 
Thomas, E. L., Bell, J. D., Kemp, G. J. and Cuthbertson, D. J. (2012) Polycystic ovary 
syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis 
compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of 
obesity and insulin resistance. J Clin Endocrinol Metab. 97, 3709-3716 
18 Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., 
Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., Pirmohamed, M. and Kemp, G. 
J. (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, 
patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 7, e50117 
19 Kemp, G. J., Roberts, N., Bimson, W. E., Bakran, A., Harris, P. L., Gilling-Smith, G. 
L., Brennan, J., Rankin, A. and Frostick, S. P. (2001) Mitochondrial function and oxygen 
supply in normal and in chronically ischemic muscle: a combined 31P magnetic resonance 
Cuthbertson et al. 2013   15 
 
 
 
spectroscopy and near infrared spectroscopy study in vivo. Journal of vascular surgery. 34, 
1103-1110 
20 Sleigh, A., Stears, A., Thackray, K., Watson, L., Gambineri, A., Nag, S., Campi, V. I., 
Schoenmakers, N., Brage, S., Carpenter, T. A., Murgatroyd, P. R., O'Rahilly, S., Kemp, G. J. 
and Savage, D. B. (2012) Mitochondrial oxidative phosphorylation is impaired in patients 
with congenital lipodystrophy. J Clin Endocrinol Metab. 97, E438-442 
21 Bajpeyi, S., Pasarica, M., Moro, C., Conley, K., Jubrias, S., Sereda, O., Burk, D. H., 
Zhang, Z., Gupta, A., Kjems, L. and Smith, S. R. (2011) Skeletal muscle mitochondrial 
capacity and insulin resistance in type 2 diabetes. J Clin Endocrinol Metab. 96, 1160-1168 
22 Praet, S. F., De Feyter, H. M., Jonkers, R. A., Nicolay, K., van Pul, C., Kuipers, H., 
van Loon, L. J. and Prompers, J. J. (2006) 31P MR spectroscopy and in vitro markers of 
oxidative capacity in type 2 diabetes patients. Magma. 19, 321-331 
23 Petersen, K. F., Dufour, S., Befroy, D., Garcia, R. and Shulman, G. I. (2004) Impaired 
mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N 
Engl J Med. 350, 664-671 
24 Morino, K., Petersen, K. F., Dufour, S., Befroy, D., Frattini, J., Shatzkes, N., Neschen, 
S., White, M. F., Bilz, S., Sono, S., Pypaert, M. and Shulman, G. I. (2005) Reduced 
mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-
resistant offspring of type 2 diabetic parents. The Journal of clinical investigation. 115, 3587-
3593 
25 Hancock, C. R., Han, D. H., Chen, M., Terada, S., Yasuda, T., Wright, D. C. and 
Holloszy, J. O. (2008) High-fat diets cause insulin resistance despite an increase in muscle 
mitochondria. Proc Natl Acad Sci U S A. 105, 7815-7820 
26 Toledo, F. G., Menshikova, E. V., Azuma, K., Radikova, Z., Kelley, C. A., Ritov, V. 
B. and Kelley, D. E. (2008) Mitochondrial capacity in skeletal muscle is not stimulated by 
weight loss despite increases in insulin action and decreases in intramyocellular lipid content. 
Diabetes. 57, 987-994 
27 Sleigh, A., Raymond-Barker, P., Thackray, K., Porter, D., Hatunic, M., Vottero, A., 
Burren, C., Mitchell, C., McIntyre, M., Brage, S., Carpenter, T. A., Murgatroyd, P. R., 
Brindle, K. M., Kemp, G. J., O'Rahilly, S., Semple, R. K. and Savage, D. B. (2011) 
Mitochondrial dysfunction in patients with primary congenital insulin resistance. The Journal 
of clinical investigation. 121, 2457-2461 
28 Sinha, R., Dufour, S., Petersen, K. F., LeBon, V., Enoksson, S., Ma, Y. Z., Savoye, 
M., Rothman, D. L., Shulman, G. I. and Caprio, S. (2002) Assessment of skeletal muscle 
triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese 
adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes. 
51, 1022-1027 
29 Thomas, E. L., Hamilton, G., Patel, N., O'Dwyer, R., Dore, C. J., Goldin, R. D., Bell, 
J. D. and Taylor-Robinson, S. D. (2005) Hepatic triglyceride content and its relation to body 
adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. 
Gut. 54, 122-127 
Cuthbertson et al. 2013   16 
 
 
 
30 Szendroedi, J., Kaul, K., Kloock, L., Straßburger, K., Schmid, A. I., Chmelik, M., 
Kacerovsky, M., Kacerovsky-Bielesz, G., Prikoszovich, T. and Brehm, A. (2013) Lower 
fasting muscle mitochondrial activity relates to hepatic steatosis in humans. Diabetes Care, 
DC_131359 
31 Brehm, A., Krssak, M., Schmid, A. I., Nowotny, P., Waldhausl, W. and Roden, M. 
(2006) Increased lipid availability impairs insulin-stimulated ATP synthesis in human 
skeletal muscle. Diabetes. 55, 136-140 
32 Szendroedi, J., Schmid, A. I., Chmelik, M., Toth, C., Brehm, A., Krssak, M., 
Nowotny, P., Wolzt, M., Waldhausl, W. and Roden, M. (2007) Muscle mitochondrial ATP 
synthesis and glucose transport/phosphorylation in type 2 diabetes. PLoS medicine. 4, e154 
33 Kacerovsky, M., Brehm, A., Chmelik, M., Schmid, A. I., Szendroedi, J., Kacerovsky-
Bielesz, G., Nowotny, P., Lettner, A., Wolzt, M., Jones, J. G. and Roden, M. (2011) Impaired 
insulin stimulation of muscular ATP production in patients with type 1 diabetes. Journal of 
internal medicine. 269, 189-199 
34 Kacerovsky-Bielesz, G., Kacerovsky, M., Chmelik, M., Farukuoye, M., Ling, C., 
Pokan, R., Tschan, H., Szendroedi, J., Schmid, A. I., Gruber, S., Herder, C., Wolzt, M., 
Moser, E., Pacini, G., Smekal, G., Groop, L. and Roden, M. (2012) A single nucleotide 
polymorphism associates with the response of muscle ATP synthesis to long-term exercise 
training in relatives of type 2 diabetic humans. Diabetes Care. 35, 350-357 
35 Szendroedi, J., Zwettler, E., Schmid, A. I., Chmelik, M., Pacini, G., Kacerovsky, G., 
Smekal, G., Nowotny, P., Wagner, O., Schnack, C., Schernthaner, G., Klaushofer, K. and 
Roden, M. (2008) Reduced basal ATP synthetic flux of skeletal muscle in patients with 
previous acromegaly. PLoS One. 3, e3958 
36 Schmid, A. I., Schrauwen-Hinderling, V. B., Andreas, M., Wolzt, M., Moser, E. and 
Roden, M. (2012) Comparison of measuring energy metabolism by different (31) P-magnetic 
resonance spectroscopy techniques in resting, ischemic, and exercising muscle. Magnetic 
resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / 
Society of Magnetic Resonance in Medicine. 67, 898-905 
37 Befroy, D. E., Rothman, D. L., Petersen, K. F. and Shulman, G. I. (2012) (3)(1)P-
magnetization transfer magnetic resonance spectroscopy measurements of in vivo 
metabolism. Diabetes. 61, 2669-2678 
38 Korenblat, K. M., Fabbrini, E., Mohammed, B. S. and Klein, S. (2008) Liver, muscle, 
and adipose tissue insulin action is directly related to intrahepatic triglyceride content in 
obese subjects. Gastroenterology. 134, 1369-1375 
39 Lomonaco, R., Ortiz-Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, 
J., Gastaldelli, A., Harrison, S., Tio, F. and Cusi, K. (2012) Effect of adipose tissue insulin 
resistance on metabolic parameters and liver histology in obese patients with nonalcoholic 
fatty liver disease. Hepatology. 55, 1389-1397 
40 Alligier, M., Gabert, L., Meugnier, E., Lambert-Porcheron, S., Chanseaume, E., 
Pilleul, F., Debard, C., Sauvinet, V., Morio, B., Vidal-Puig, A., Vidal, H. and Laville, M. 
Cuthbertson et al. 2013   17 
 
 
 
(2013) Visceral fat accumulation during lipid overfeeding is related to subcutaneous adipose 
tissue characteristics in healthy men. J Clin Endocrinol Metab. 98, 802-810 
 
 
